| Title | Author(s) | Year | View Count |  | Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma | Omata, M; Lesmana, LA; Tateishi, R; Chen, PJ; Lin, SM; Yoshida, H; Kudo, M; Lee, JM; Choi, BI; Poon, RTP; Shiina, S; Cheng, AL; Jia, JD; Obi, S; Han, KH; Jafri, W; Chow, P; Lim, SG; Chawla, YK; Budihusodo, U; Gani, RA; Lesmana, CR; Putranto, TA; Liaw, YF; Sarin, SK | 2010 | 69 |
| Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B | Chang, TT; Liaw, YF; Wu, SS; Schiff, E; Han, KH; Lai, CL; Safadi, R; Lee, SS; Halota, W; Goodman, Z; Chi, YC; Zhang, H; Hindes, R; Iloeje, U; Beebe, S; Kreter, B | 2010 | 90 |
 | Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from globe and 015 studies in chronic hepatitis B patients | Hsu, CW; Chen, YC; Liaw, YF; Gane, E; Manns, M; Zeuzem, S; Wang, Y; Lai, CL; Hou, J; Leung, N; Bzowej, N; Niu, J; Jia, J; Hwang, SG; Cakaloglu, Y; Ren, H; Papatheodoridis, G; Chen, Y; Bao, W; Lopez, P | 2009 | 308 |
 | Errata: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update | Liaw, YF; Leung, N; Kao, JH; Piratvisuth, T; Gane, E; Han, KH; Guan, R; Lau, GKK; Locarnini, S; The Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver | 2008 | 127 |
| Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis B: results from studies ETV-022, -027 and -901. | Liaw, YF; Chang, TT; Wu, SS; Schiff, ER; Han, KH; Lai, CL; Safadi, R; Lee, SS; Halota, W; Goodman, ZD; Zhang, H; Hindes, R; Hoeje, U; Beebe, S; Kreter, B | 2008 | 200 |
| Long-term follow-up of entecavir treated protocol-defined non responders in rollover study ETV-901 | Sherman, M; Rizzetto, M; Lai, CL; Liaw, YF; Gadano, A; Jacobson, IM; Schiff, ER; Yang, J; Colonno, R; Kreter, B; Hindes, R | 2007 | 123 |
| Telbivudine versus lamivudine in patients with chronic hepatitis B | Lai, CL; Gane, E; Liaw, YF; Hsu, CW; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, NV; Di Bisceglie, AM; Zeuzem, S; Moon, YM; Goodman, Z; Chao, G; Constance, BF; Brown, NA | 2007 | 258 |
| Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis B | Naoumov, N; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Heathcote, EJ; Rasenack, J; Bzowej, N; Chao, G; Brown, N | 2006 | 106 |
| Entecavir (ETV) vs. Adefovir (ADV): HBV DNA reduction of viral load in chronically infected HBeAg(+) nucleoside naive adults in a 12-week | Sherman, M; Hann, HW; Jeffers, L; Min, A; Leung, N; Peng, CY; Liaw, YF; Sollano, J; Lesmana, L; Yuen, RMF; Zhu, J; Mencarini, K; Colonno, R; Cross, A; Wilber, R; Lopez-Talavera, JC | 2006 | 145 |
| Phase III comparison of telbivudine vs lamivudine in HBeAg-positive patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year | Gane, E; Lai, CL; Liaw, YF; Thongsawat, S; Wang, YM; Cheng, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 128 |
| Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients | Zeuzem, S; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N | 2006 | 124 |
| High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B | Lin, CL; Tsai, SL; Lee, TH; Chien, RN; Liao, SK; Liaw, YF | 2005 | 207 |
| Telbivudine (LdT) vs. lmivudine for chronic Hepatitis B: First-year results from the international phase III GLOBE trial | Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, . | 2005 | 161 |
| Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study) | Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Chen, Y; Heathcote, J; Rasenack, J; Bzowej, N; Naoumov, N; Chao, G; Fielman, B; Brown, N; and the GLOBE Study Group, . | 2005 | 162 |
| Spontaneous HBsAg seroclearance confers excellent prognosis except in patients with cirrhosis [4] (multiple letters) | Chen, YC; Liaw, YF; Yuen, MF; Wong, DKH; Lai, CL | 2004 | 43 |
| Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B | Perrillo, RP; Lai, CL; Liaw, YF; Dienstag, JL; Schiff, ER; Schalm, SW; Heathcote, EJenny; Brown, NA; Atkins, M; Woessner, M; Gardner, SD | 2002 | 110 |
| Effects of extended lamivudine therapy in asian patients with chronic hepatitis B | Liaw, YF; Leung, NWY; Chang, TT; Guan, R; Tai, DI; Ng, KY; Chien, RN; Dent, J; Roman, L; Edmundson, S; Lai, CL | 2000 | 73 |
| Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group | Liaw, YF; Leung, NW; Chang, TT; Guan, R; Tai, DI; Ng, KY; Chien, RN; Dent, J; Roman, L; Edmundson, S; Lai, CL | 2000 | 136 |
| 12 months lamivudine (100mg od) therapy improves liver histology: results of a placebo controlled multicentre study in Asia | Lai, CL; Liaw, YF; Leung, NWY; Chang, TT; Guan, R; Tai, DI; Ng, KY; Wu, PC; Dent, JC; Gray, DF | 1997 | 215 |
|
